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The in vitro biological activity on the MDA-MB-231 triple-negative breast cancer (TNBC) cell line of 
two different series of anionic Pt(II) organometallic complexes was tested. For the first time, the cytotoxic 
activity of anionic Pt(II) complexes has been observed. The anionic compounds of general formula 
NBu4[(C^N)Pt(O^O)], where (C^N) stands for the cyclometalated form of 2-phenylpyridine (H(PhPy)), 
2-thienylpyridine (H(Thpy)) or 2-benzo[h]quinoline (H(Bzq)) feature two different (O^O) chelated 
ligands: the tetrabromocatechol [BrCat]2- (1-3) or alizarine [Aliz]2- (4-6). Complexes 1-6 displayed a 
significant cytotoxic effect on the studied cell line (1.9-52.8 M IC50 range). For BrCat containing 
complexes, the biological activity was indipendent of the nature of the coordinated (C^N) ligand. In the 
case of 4-6 instead, the cytotoxicity (significantly low for 4) was concomintantly induced by  the presence 
of either the PhPy and the [Aliz]2- ligands. Since complexes 1-6 are emissive in solution, the potential use 
of complex 4 as theragnostic agent was investigated by confocal analysis. The fluorescence signal from 
MDA-MB-231 cells incubated with 4 indicated the localization of the compound into the cytosol region. 
Introduction 
Owe to the numerous side effects, long term resistance and clinical limitation of the well-known 
first generation  Pt(II) anticancer complex cisplatin (Chart 1a),1 numerous DNA binding 
platinum drugs have been developed over the years.2,3 The so called second generation platinum 
drugs include Pt(II) complexes which deviate from the cisplatin template as the metal centre 
  
experiences a different ligand field, leading to a modulation of the electronic, steric hindrance and 
basicity features.4,5 Among these, the most effective carboplatin (Chart 1b), presents higher 
solubility and stability than cisplatin and lower side effects.6 The third generation Pt(II) antitumor 
drugs, incorporate, instead, different ammines and leaving groups, and among this category 
emerges as the most popular example, like the water soluble oxaliplatin (Chart 1c), embedding 
two chelating ligands and exhibiting a broader spectrum of activity than cisplatin or carboplatin.7-9  
Differently from the mechanism of action of cisplatin and its previously described derivatives, 
covalently binding Pt(II) complexes, incorporating a planar aromatic ligand, such as 1,10-
phenanthroline, anthraquinone, acridine etc., may intercalate between two adjacent DNA base 
pairs stabilized through − stacking stabilization,10 and/or may subsequently coordinately bind 
to DNA by losing a labile leaving group.11 Intercalation causes thus DNA to lose its regular 
helical structure.14-16 As evidenced by a comprehensive study on a series of positively charged 
Pt(II) complexes bearing aromatic (N^N) ligands,17-21 (Chart 2a-c) the cytotoxicity is influenced 
by the extension of the aromatic core, as well as by the charge (positive in the examined cases), 
solubility and effective Pt(II) complex cellular uptake, following a mechanism not yet fully 
elucidated, but different from the one followed by cisplatin.13,17-18,22-23 Several studies have indeed 
suggested an activity of these Pt(II) complex at a mitochondrial level, while X-ray structures24 
have demonstrated that the aromatic ligands insert between the base pairs of DNA.25-27  
Due to their capability of forming repair resistant lethal Pt-DNA crosslinks, bis-chelated Pt(II) 
complexes have been found more efficient than their counterparts embedding monodentate 
ligands.13 Following such an approach, Mitra et al. synthesized the catecholate containing  Pt(II) 
neutral complexes [(N^N)Pt(O^O)]28 (Chart 2b) based on carboplatin and oxaliplatin archetypes 
(Chart 1b,c) and by performing time-dependent UV-visible spectral studies they demonstrated 
the breakage of the Pt-O bond in the presence of an excess of glutathione (GSH), which can be at 
the basis of the observed activity triggered by the thus generated free owing to the generated free 
coordinating site.  
Regarding the “orphan” tumours, one of the most aggressive is the triple-negative breast cancer 
(TNBC), which displays evinces a negative response to drugs due to the lack in the main three 
receptors, common targets of the therapy against breast cancer.29,30 Indeed, TNBC does not 
respond to hormonal therapy medicines or medicines that target HER2 protein receptors. For this 
reason, it is necessary to introduce a new detecting methodology and treatment for TNBC. In the 
last years, many research groups have attempted to overcome this limit by focalizing their 
attention on the development of new therapeutic agents, characterized by the capability to allow a 
  
targeted imaging together with the induction of a cytotoxic effect in TNBC tumour cells.29,30 
Taking into consideration this premise, we tested the in vitro biological activity on the MDA-MB-
231 cell line. 
To the best of our knowledge, anionic Pt(II) complexes have never been tested for their biological 
properties. Herein, we have considered a series of ionic complexes of general formula 
NBu4[(C^N)Pt(O^O)], featuring the tetrabutylammonium cation and the Pt(II) organometallic 
anion [(C^N)Pt(O^O)], where (C^N) stands for the cyclometalated form of 2-phenylpyridine 
(H(PhPy)), 2-thienylpyridine (H(Thpy)) or 2-benzo[h]quinoline (H(Bzq)), while (O^O) represents 
either the dianion of the tetrabromocatechol (H2(BrCat), (Chart 3, complexes 1-3)
31 or the 
dianionic form of the alizarine (H2(Aliz)). (Chart 3, complexes 4-6) To complete the series in 
order to probe the eventual activity of the newly introduced [Aliz]2- molecular fragment, the 
neutral complex 7 (Chart 3), parent of the cisplatin archetype, was synthesized and tested. The 
Pt(II) complexes were selected taking into account the peculiar molecular structure, ionic in 
nature, whose anion contains a Pt(II) centre bonded to a cyclometalated (C^N) ligand32-34 and 
coordinated to a chelating (O^O) fragment. In particular, it has previously been documented that a 
series of cycloplatinated complexes showed promising IC50 values (µM) against Sarcoma 18 
cells.35,36 Instead, both the H2(BrCat) and H2(Aliz) ligands were chosen due to the fact that they 
may be prone to Pt-O bond breaking in intracellular medium, favouring DNA covalent binding.  
Finally, compared to [BrCat]2-, the [Aliz]2- fragment presents a more extended aromatic core 
combined with a chemical structure similar to those of the already tested antitumor intercalating 
aromatic molecules doxorubicin (Chart 2e) 37-42 and mitoxantrone (Chart 2f).43 
In addition, besides potential anticancer activity, the extended aromatic system and the acidic 
character of the hydroxyl substituents could confer to the anthraquinone-derived molecule a 
fluorescent behaviour.44 Accordingly, its incorporation into the Pt(II) complexes is expected to 
contribute to the development of new compounds as cellular labels or probes for imaging.  
Results and discussion 
Synthesis 
The cyclometalated anionic Pt(II) complexes 1-3 derived from H2(BrCat) were synthesized as 
previously reported.33 Complexes 4-6 were prepared starting from the respective cycloplatinated 
precursors I-III (Scheme 1) by adapting an already reported procedure.45 Complexes bearing the 
cyclometalated ligands PhPy (4) and ThPy (5) were prepared starting from a mononuclear 
intermediate, obtained by microwave assisted synthesis, as previously reported,45 while for 
  
complex 6 incorporating the Bzq fragment, a chloro-bridged binuclear cycloplatinated precursor 
was used (Scheme 1).46 The treatment of I-III with H2(Aliz) in basic media (NBu4OH)
47 afforded 
the anionic square-planar Pt(II) complexes 4-6, in moderate to high yields.  
Complex 7 was synthesized starting from cisplatin, which was prepared according to an already 
described microwave assisted procedure,48 followed by treatment with AgNO3 as halogen 
scavenger and subsequent coordination of [Aliz]2- in basic media (Scheme 2).  
The newly synthesized 4-7 complexes were fully characterized by FT-IR and 1H-, 13C-NMR 
spectroscopies, ESI-MS, melting points and elemental analysis. Considering the IR spectra of 
complexes 4-6, the coordination of the [Aliz]2- group was confirmed by the shift of the C=O and 
C-O stretching bands from 1663 cm-1 and 1460 cm-1, respectively, in the free H2(Aliz) ligand to 
ca. 1635 and ca. 1442 cm-1 for complexes 4-6. The C-H aliphatic stretching bands (ca. 2900 cm-1) 
associated to the presence of the [NBu4]
+ counterion confirmed the negative charge of the Pt(II) 
thus synthesized complexes.  
However, due to the asymmetrical structure of the H2(Aliz) ligand, upon complexation to the 
Pt(II) metal centre, two cis/trans geometrical isomers (with respect to the relative position of the 
N-coordinated atom and the more sterically hindered O-chelated atom) could be expected.32 The 
1H-NMR spectra were characterized by the splitting of the signal associated with the proton in 
alfa position with respect to the cyclometalated nitrogen atom, so accounting for the presence of 
the two cis/trans isomers that, according to the corresponding signal integration, resulted in 1:0.7 
(4), 1:1 (5), 1:1(6) cis/trans ratios. Moreover, the signals associated to the aliphatic protons in the 
upfield region of the spectrum confirmed the presence of the [NBu4]
+ counterion in stoichiometric 
ratio with respect to the aromatic protons, evidence of the ionic nature of complexes 4-6.  
The formation of 4-6 was also confirmed by 13C-NMR spectroscopy. ESI-MS analyses of 
complexes, carried out via direct infusion in the negative mode, showed an isotope cluster, 
centred at m/z 587.55 (4), 593.28 (5), 611.68 (6) due to the natural abundances, and corresponding 
to the [(C^N)Pt(Aliz)]- complex anion. The formation of complex 7, instead, was confirmed by 
the analysis of the FT-IR spectrum, displaying the signal associated to the NH3 groups at 3434 
cm-1. Considering the signals relative to the coordinated [Aliz]2- fragment, the C=O and C-O 
stretching are shifted at 1625 and 1490 cm-1, respectively, in complex 7, compared with 1663 and 
1460 cm-1 in the free ligand. The 1H-NMR spectrum is consistent with the chemical structure of 
complex 7, although showing a broad single signal accounting for both NH3 groups.  
 
 
  
 
Photophysical properties 
The photophysical properties in solution of 1-3 have been extensively investigated previously.33 
For a direct comparison, the absorption and emission spectra were re-proposed in the ESI 
(Figures SI-1,2) and the data summarized in Table 1. 
The UV-Vis absorption spectra in DMSO solution of the Aliz series 4-7 are shown in Figure 1.  
All the cyclometalated complexes 4-6 displayed intense bands in the ultraviolet region between 
280 and 330 nm assigned to the allowed 1LC(π-π*) transitions localized respectively on the PhPy, 
ThPy and Bzq ligand49-51 The low-energy absorption bands between 330 and 650 nm of 4-7 were 
instead attributed to a mixed (MLCT-LC) character, which predominantly involved the chelating 
ligand, in agreement with the experimental and theoretical electronic spectra of the Aliz 
molecule.52,53 
All the new anionic compounds displayed emissive properties in solution in the red region of the 
electromagnetic spectrum (Figure 2 and Table 1), showing a structured band arising from the 
MLCT-LC transition. 
 
Evaluation of in vitro cytotoxic activity 
It has been reported that the Pt(II) anticancer drug cycloplatam, important for overcoming drug 
resistance to cisplatin (Chart 4)54 exists under two isomeric cis/trans forms, the biological 
activity of any single isomeric form remained first unknown, but recently, being still unknown. 
Recently, the two bioactive isomers have been separated and tested showing equal anticancer 
activity.55,56  
For the NBu4[(C^N)Pt(Aliz)] 4-6 complexes, NMR spectroscopy indicate the presence of 
geometrical isomers. Separation of the two isomers through HPLC, both with chiral and achiral 
columns under reverse phase conditions, have been attempted but was not successful. 
Accordingly, in the present study, we preliminary tested the cytotoxic properties of the cis/trans 
mixture for the 4-6 alizarin containing complexes.  
As shown in Table 2, all the complexes exerted a significant cytotoxic effect on triple-negative 
breast cancer cell line MDA-MB-231, with IC50 values ranging from 1.9 to 127 µM. 
As exhibited by Table 2, all the complexes 1-3 with dianion [BrCat]2- showed a good cytotoxic 
activity on MDA-MB-231 with values of IC50 around 40 µM, independently from the ligand used 
in the complex. On the contrary, when Aliz was used as dianion as in species 4-6, significant 
differences were evinced in function of the cyclometalated (C^N) ligand employed in the 
  
coordination sphere of the Pt(II) centre. In particular, the cytotoxic activity of 4, in which the 
PhPy was bound to the Pt(II), resulted in a very low value of IC50 (IC50 equal to 1.9±1.6 µM). 
Complex 4, showed somewhat significant cytotoxic effect on MDA-MB-231 tumour cells 
compared to normal not transformed vascular smooth muscle cells, showing a ten-fold higher IC50 
value (12.5±1.0 µM vs 1.9±1.6 µM). With the aim to evaluate the capability of H2(Aliz) ligand to 
influence alone the cytotoxic activity of a complex, compound 7 was synthetized. The potency of 
the cytotoxic effect decreased in comparison to cisplatin’s value on MDA-MB-231 (IC50 equal to 
126.9±2.7 µM for 7 and 59.4 µM for cisplatin).23 This data confirmed that the matching between 
the cyclometalated H(PhPy) moiety and [Aliz]2- ligand, in the complexes, was necessary to 
contribute to cytotoxic activity of the compound. In addition, we evaluated the cytotoxicity effect 
of ligands utilized for the synthesis of the complexes. As shown in Table 2, BrCat was the only 
ligand that showed a significant cytotoxic effect with an IC50 value similar to the complexes, 
while Aliz, ThPy, PhPy and Bzq were inactive. These data suggest a more potent cytotoxic effect 
of complexes compared to single ligands.   
In order to investigate the molecular mechanisms underlying the cytotoxic effect of these 
complexes, we analysed the effect of 4 on cell-cycle progression in MDA-MB-231 cell line. 
Incubation of MDA-MB-231 with 10% FCS shows a 15.9% of cells in S phase (Figure 3). The 
addition of 5 µM of complex 4 to the medium determined an accumulation of cells in S phase 
(20.4%) associated to a concomitant reduction of cells in G2/M phase, from 33.7% to 22.7%. 
Taken together, these results indicated that complex 4 exerts an antiproliferative/cytotoxic action 
by blocking the progression of the cells through the S phase of the cell cycle. 
The potential use of complex 4 as theragnostic agent was investigated by measuring the 
fluorescence signal from MDA-MB-231 cells incubated with 2.5 and 5 µM concentration of the 
compound. As shown in Figure 2, we detected a positive signal after 3h exposure of the cells 
with 5 µM of complex 4. Moreover, confocal analysis indicated that the majority of the compound 
is localized into the cytosol in the perinuclear region (Figure 4).  
Conclusions 
A series of cyclometalated anionic complexes of general formula NBu4[(C^N)Pt(O^O)] were 
synthesized,  spectroscopically characterized and tested for their cytotoxicity against MDA-MB-231 triple 
negative breast cancer cell line.  A  2-phenylpyridine (H(PhPy)), 2-thyenylpyridine (H(Thpy)) or 2-
benzo[h]quinoline (H(Bzq)) were respectively coordinated as (C^N) ligands, while alizarine (Aliz) and 
tetrabromocatechol (BrCat) were used as a (O^O) chelated ligand.  
  
The Aliz based complexes NBu4[(C^N)Pt(Aliz)] exhibited an important cytotoxic effect on the 
studied cell line (1.9-127 M IC50 range), more efficient compared with the catecholate 
containing series. By studying the effect of the best performing 4 (with a IC50 of 1.9 M) onto the 
MDA-MB-231 cycle progression, it was evidenced that the Pt(II) species exert an 
antiproliferative/cytotoxic effect by blocking the progression of the cell cycle in its S phase.  
Since all the investigated complexes are emissive in solution, the most efficient complex 
NBu4[(PhPy)Pt(Aliz)] was studied by confocal analysis. The fluorescence signal observed from 
the MDA-MB-231 cells incubated with NBu4[(PhPy)Pt(Aliz)]  indicated the presence of the Pt(II) 
compound into the cytosol region, for which its potential use as a theragnostic agent could be 
considered.      
Experimental 
General considerations 
All commercially available chemicals were purchased from Sigma Aldrich or Alfa Aesar and 
were used without further purification. Cycloplatinated precursors I-III and complexes 1-3 were 
synthesized as already reported.33 Microwave assisted syntheses were carried out using a CEM 
Discover Synthesis Unit (CEM Corp., Matthews, NC). Melting points were determined with a Leica 
DMLP polarising microscope equipped with a Leica DFC280 camera and a CalCTec (Italy) heating stage. 
Elemental analyses were performed with a PerkinElmer 2400 analyzer CHNS/O. 
 
Spectroscopy and spectrometry 
IR spectra (KBr pellets) were recorded on a Spectrum One Perkin-Elmer FT-IR spectrometer. 1H-
NMR spectra were recorded on a Brucker WH-300 spectrometer in deuterated solvents with TMS 
as internal standard. MS analyses were performed by using a Thermo Finnigan (MA, USA) LCQ 
Advantage system MS spectrometer with an electronspray ionisation source and an ‘Ion Trap’ 
mass analyser. The MS spectra were obtained by direct infusion of a sample solution in MeOH 
under ionisation, ESI negative. Spectrofluorimetric grade DMSO was used for the photophysical 
investigations in solution, at room temperature. A Perkin Elmer Lambda 900 spectrophotometer 
was employed to obtain the UV/Vis absorption spectra, using quartz cuvettes of 1 cm path length. 
Steady-state emission spectra were recorded on a Horiba Jobin Yvon Fluorolog 3 
spectrofluorimeter, equipped with a Hamamatsu R-928 photomultiplier tube. The emission 
  
quantum yields of 4-7 were obtained using the optical dilution method57 using cresyl violet 
perchlorate in methanol as reference standard (=0.54).58 
 
Synthesis 
Preparation of NBu4[(PhPy)Pt(O^O)] (4). Two equivalents of H2(Aliz) (22 mg, 0.093 mmol) 
were added to a solution of I (50 mg, 0.093 mmol) in 20 ml of degassed ethanol. In this solution, 
NBu4OH (0.18 ml, 0.186 mmol) was added and the mixture was stirred for 24 hours under reflux. 
The crude product was concentrated, and water was added. The solid was isolated by filtration 
and washed with water and diethyl ether. Dark blue solid, yield 61 %; m.p. 139°C; 1H-NMR (d6-
DMSO, 300 MHz, TMS) δ =  9.22 (d, JH-H= 5.43 Hz, 1H), 8.96 (d, JH-H= 5.43 Hz, 0.7H), 8.11-
8.08 (m, 1H), 8.01-7.98 (m, 2.1H), 7.94-7.89 (d, 0.7H), 7.84-7.82 (m, 3.5H), 7.65-7.53 (m, 6.4H), 
7.39-7.36 (m, 2H), 7.30-7.27 (m, 0.7H), 7.18-7.17 (m, 1.3H), 7.05-6.94 (m, 2.7H), 6.51 (d, JH-H= 
3.21 Hz, 0.7H), 6.48 (d, JH-H= 3.06 Hz, 1H), 3.07 (s, 13.6H), 1.47 (s, 13.6H), 1.21 (s, 13.6H), 0.84 
(s, 20.4H); 13C-NMR (CDCl3, 300 MHz, TMS) δ =182.88, 182.78, 182.26, 181.65, 176.75, 
176.65, 170.42, 170.40, 167.39, 167.35, 144.44, 144.20, 144.11, 143.92, 136.74, 136.58, 136.54, 
136.30, 134.76, 134.74, 134.67, 133.15, 132.25, 132.12, 132.00, 131.99, 131.64, 131.46, 130.28, 
129.43, 129.34, 129.28, 126.50, 126.44, 126.16, 126.09, 125.92, 122.99, 122.89, 122.60, 122.13, 
122.02, 121.75, 121.50, 121.29, 119.81, 118.81, 118.52, 118.03, 117.80, 58.26, 23.83, 19.42, 
13.53; FT-IR (KBr) ν (cm-1) = 2959, 2931, 2872, 1633, 1511, 1443, 1339, 1301, 1281, 1257, 761, 
721; E.A. calculated (%) for C37H42N2O4Pt: C, 57.43; H, 5.47; N, 3.62; found: C, 57.83; H, 5.39; 
N, 3.49; MS (ESI) m/z 587.55 [M]- 
 
Preparation of NBu4[(ThPy)Pt(Aliz)] (5). Following the same procedure described for the 
synthesis of 4, the reaction was conducted using II (100 mg, 0.18 mmol), H2(Aliz) (43 mg, 0.18 
mmol) and NBu4OH (0.40 ml, 0.36 mmol). Dark blue solid, yield 72 %; m.p. 108°C; 
1H-NMR 
(d6-DMSO, 300 MHz, TMS) δ =  9.18 (d, J=5.46 Hz, 1H), 8.91 (d, J=5,46 Hz, 1H), 8.18-8.13 (m, 
1H), 8.07-8.05 (m, 3H), 7.87-7.82 (m, 1H), 7.72-7.65 (m, 6H), 7.45-7.42 (m, 2H), 7.36-7.34 (m, 
1H), 7.28-7.27 (m, 2H), 7.16-7.10 (m, 3H), 7.05-7.02 (m, 2H), 6.60 (d, 1H), 3.14 (s, 16H), 1.54 
(s, 16H), 1.29 (s, 16H), 0.91 (s, 24 H); 13C-NMR (CDCl3, 300 MHz, TMS) δ =182.76, 182.70, 
182.17, 181.67, 177.17, 173.37, 170.89, 168.02, 163.39, 163.29, 150.25, 149.69, 147.99, 147.70, 
137.74, 137.66, 137.39, 137.36, 136.50, 136.23, 134.65, 134.61, 133.41, 133.10, 132.56, 132.20, 
132.09, 131.69, 131.53, 131.38, 128.02, 127.02, 126.48, 126.19, 126.03, 125.93, 122.69, 121.44, 
  
121.25, 119.70, 118.81, 118.64, 117.88, 116.72, 116.66, 116.44, 57.82, 23.64, 19.26, 13.46; FT-
IR (KBr) ν (cm-1) = 2959, 1635, 1601, 1513, 1475, 1444, 1257, 720; E.A. calculated (%) for 
C35H40N2O4PtS: C, 53.90; H, 5.17; N, 3.59; found: C, 54.15; H, 5.29; N, 3.19; MS (ESI) m/z 
593.28 [M]- 
  
Preparation of NBu4[(Bzq)Pt(Aliz)] (6). Following the same procedure described for the 
synthesis of 4, the reaction was conducted using III (100 mg, 0.12 mmol), H2(Aliz) (59 mg, 0.24 
mmol) and NBu4OH (0.48 ml, 0.48 mmol). Purple solid, yield 55 %; m.p. 196 °C; 
1H-NMR (d6-
DMSO, 300 MHz, TMS) δ = 9.46 (d, 1H), 9.24 (d, 1H), 8.62-8.58 (m, 2H), 8.20-8.18 (m, 2H), 
8.10-8.06 (m, 2H), 7.88-7.83 (m, 2H), 7.76-7.71 (m, 9H), 7.61-7.53 (m, 4H) 7.49-7.45 (m, 2H), 
7.39-7.36 (m, 1H), 6.66 (d, 1H), 6.63 (d, 1H), 3.14 (s, 16H), 1.53 (s, 16H), 1.27 (s, 16H), 0.91 (s, 
24H); 13C-NMR (CDCl3, 300 MHz, TMS) δ =182.94, 182.86, 182.82, 182.36, 182.35, 182.34, 
182.32, 182.31, 181.77, 181.74, 181.71, 176.85, 174.13, 174.16 174.10, 175.09, 174.06, 174.03, 
168.83, 148.95, 148.58, 148.32, 148.29, 141.95, 141.91, 141.08, 140.52, 136.36, 135.54, 135.41, 
134.79, 134.72, 133.29, 133.19, 132.15, 132.02, 131.64, 131.47, 130.92, 130.29, 129.15, 129.03, 
126.56, 126.20, 126.11, 125.96, 122.87, 121.48, 120.90, 120.73, 119.81, 119.63, 118.09, 116.79, 
57.99, 23.67, 19.21, 13.31; FT-IR (KBr) ν (cm-1) =2958, 2871, 1634, 1512, 1443, 1339, 1298, 
1280, 1256, 821, 717; E.A. calculated (%) for C39H42N2O4Pt: C, 58.71; H, 5.31; N, 3.51; found: 
C, 58.73; H, 5.25; N, 3.63; MS (ESI) m/z 611.68 [M]- 
 
 
Preparation of [(NH3)2Pt(Aliz)] (7). Cisplatin (40 mg, 0,13 mmol) and AgNO3 (43 mg, 0,26 
mmol) were suspended in 1 ml of dimethylformamide and stirred at r.t. for 12 h. The precipitated 
AgCl was filtered off and to the filtrated solution H2(Aliz) (13 mg, 0,33 mmol) and 5 eq. of 
NaOH solubilized in 4 mL of distilled water were added. The reaction mixture was stirred at r.t. 
for 5h under nitrogen atmosphere. The dark solid was filtered, washed with distilled water, 
ethanol and dichloromethane. Dark blue solid, yield 85%; m.p. >250°C. 1H-NMR (d6-DMSO, 300 
MHz, TMS) δ = 8.16-8.08 (m,2H), 7.74-7.72 (m, 2H), 7.43 (d, J=8,46 Hz, 1H), 6.42 (d, J=8,13 
Hz, 1H), 3.64 (s, 6H) ; FT-IR (KBr) ν (cm-1) = 3434, 1626, 1490, 1384, 1286, 1208, 715. E.A. 
calculated (%) for C14H12N2O4Pt: C, 35.98; H, 2.59; N, 5.99; found: C, 36.03; H, 2.55; N, 5.63. 
 
 
 
  
Biological studies 
Reagents 
Dulbecco’s modified Eagle medium (DMEM), trypsin-EDTA, penicillin/streptomycin, sodium 
pyruvate, non-essential amino acid solution, fetal calf serum (FCS), plates and Petri dishes were 
purchased from EuroClone. The compounds were dissolved in dimethyl sulfoxide (DMSO) before 
performing each experiment. The maximal concentration utilized was 200 µM; cisplatin was 
tested up to 100 µM. The amount of DMSO did not exceed the 0.25% of the culture media 
volume.  
 
Cell culture 
Human triple negative cancer cell line MDA-MB-231 were cultured in DMEM supplemented 
with 10% FCS, 1% non-essential amino acids 100X, 1% penicillin/streptomycin 100X, 1% L-
glutamine 200 mM and 1% sodium pyruvate at 37°C in a humidified atmosphere (5% CO2 and 
95% air). 
 
Cell viability assay 
Sulphorhodamine B (SRB) assay was performed to assess the cell viability after treatments. 5x103 
cells/well were seeded in a 96-well tray in triplicate. After 24 h of incubation, the cells were 
treated with different concentrations of compounds. SRB assay were performed after 48h as 
previously described.24 
 
Confocal microscopy analysis 
4x104 cells/well were seeded in a 24-well tray in duplicate. After 24h of incubation, the cells were 
treated with 2.5 and 5 μM of complex 4. After 3h of incubation, the cells were washed with PBS, 
fixed with paraformaldehyde (PFA) 4% at r.t. for 10 min. After fixation, free aldehyde groups 
were removed by incubate the cells with NH4Cl 50 mM for 10 min at r.t.. Finally, the cells were 
washed three times with PBS and stored in PBS at 4°C until the confocal analysis. 
The confocal microscopy analysis has been performed with Zeiss LSM 800 by exciting the cells 
with λ = 405 nm. Fluorescence has been collected at λ = 590-670 nm.  
 
Statistical analysis 
Experimental data are expressed as mean ± S.D. The effects of the complexes versus control were 
analysed by two-tailed Student’s t test for unpaired data. The concentration of compounds 
  
required to reduce by 50% of cell viability (IC50) was calculated by 4-PL nonlinear regression 
curve (GraphPad Prism, Version 5.01). 
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Table 1. Photophysical data of compounds 1-7 in DMSO solution (1∙10-5M) at 298K. 
Complex 
Absorption max/nm 
(/M-1cm-1) 
Emission 
max/nm 
Ф(%) 
1a 
293(21072)-314(13937)-328(11313)-417(sh)-
442(9324) 
593 0.02 
2a 309(27950)-349(sh)-421(10075)-448(10303) 581, 606, 529 0.19 
3b 
319(21070)-354(11237)-378(10444)-430(sh)-
464(9141) 
621 0.04 
4 
287(32152)-422(5248)-535(sh)-571(11707)-
612(sh) 
670, 725, 790 (sh) 0.40 
5 
295(27715)-347(sh)-423(7221)-532(sh)-
569(13975)-609(sh) 
670, 725, 790 (sh) 0.25 
6 
278(28036)-321(sh)-360(8281)-436(sh)-
532(sh)-571(15800)-612(sh) 
670, 725, 790 (sh) 0.31 
7 357(5770)-421(sh)-480(sh)-557(4178) 670, 780 0.20 
 
a Complex 1-3 are reproduced from ref. 33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Cytotoxicity effect of anionic Pt(II) complexes 1-7 and their ligands on MDA-MB-231 cell 
line.  
N.A.: not active 
 
Complex IC50 (µM) 
1 52.8±3.9 
2 46.1±3.1 
3 31.7±0.6 
4 1.9±1.6 
5 18.3±2.3 
6 6.8±0.6 
7 126.9±2.7 
Aliz N.A. 
BrCat 32.7±7.3 
ThPy N.A. 
PhPy N.A. 
Bzq N.A. 
 
 
 
